Citadel Advisors
AUTL

Citadel Advisors’s Autolus Therapeutics AUTL Stock Holding History

Citadel Advisors’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.11M Buy
695,890
+236,486
+51% +$371K ﹤0.01% 7945
2026
Q1 		$634K Sell
459,404
-700,387
-60% -$1.06M ﹤0.01% 8717
2025
Q4 		$2.31M Sell
1,159,791
-4,884,452
-81% -$7.51M ﹤0.01% 5642
2025
Q3 		$9.85M Buy
6,044,243
+5,039,865
+502% +$9.85M ﹤0.01% 3297
2025
Q2 		$2.29M Buy
1,004,378
+815,470
+432% +$1.35M ﹤0.01% 5454
2025
Q1 		$293K Sell
188,908
-135,094
-42% -$274K ﹤0.01% 9663
2024
Q4 		$761K Buy
324,002
+20,994
+7% +$71K ﹤0.01% 7609
2024
Q3 		$1.1M Sell
303,008
-222,780
-42% -$888K ﹤0.01% 6685
2024
Q2 		$1.83M Sell
525,788
-160,692
-23% -$693K ﹤0.01% 5485
2024
Q1 		$4.38M Buy
686,480
+646,715
+1,626% +$4.03M ﹤0.01% 4143
2023
Q4 		$256K Buy
+39,765
New +$152K ﹤0.01% 9477
2023
Q3 		– Sell
-185,815
Closed -$442K – 14259
2023
Q2 		$442K Sell
185,815
-1,379,531
-88% -$3.27M ﹤0.01% 8207
2023
Q1 		$2.88M Sell
1,565,346
-211,753
-12% -$414K ﹤0.01% 4705
2022
Q4 		$3.38M Buy
1,777,099
+634,494
+56% +$1.6M ﹤0.01% 4548
2022
Q3 		$2.44M Sell
1,142,605
-1,011,052
-47% -$3M ﹤0.01% 5200
2022
Q2 		$6.09M Sell
2,153,657
-1,358,856
-39% -$4.14M ﹤0.01% 3443
2022
Q1 		$14.6M Buy
3,512,513
+1,814,570
+107% +$7.63M ﹤0.01% 2402
2021
Q4 		$8.81M Sell
1,697,943
-704,891
-29% -$4.23M ﹤0.01% 3281
2021
Q3 		$15.7M Sell
2,402,834
-359,920
-13% -$2.27M ﹤0.01% 2363
2021
Q2 		$18.3M Buy
2,762,754
+2,721,085
+6,530% +$16.9M ﹤0.01% 2187
2021
Q1 		$239K Buy
41,669
+22,661
+119% +$168K ﹤0.01% 11337
2020
Q4 		$170K Buy
19,008
+5,640
+42% +$60.1K ﹤0.01% 9853
2020
Q3 		$156K Sell
13,368
-565,976
-98% -$8.21M ﹤0.01% 8973
2020
Q2 		$9.29M Sell
579,344
-2,360
-0.4% -$26.2K ﹤0.01% 2313
2020
Q1 		$3.48M Buy
581,704
+570,163
+4,940% +$5.27M ﹤0.01% 3230
2019
Q4 		$152K Buy
+11,541
New +$151K ﹤0.01% 8354
2019
Q3 		– Sell
-71,285
Closed -$1.15M – 9137
2019
Q2 		$1.15M Buy
+71,285
New +$1.59M ﹤0.01% 5473

Other funds holding AUTL

MCO
MAK Capital One New York $714M AUM 68.07% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $32.9B AUM 23.66% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $26.6M AUM 10.36% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $635M AUM 28.07% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $141B AUM 34.18% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
BNP Paribas Asset Management
BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Citadel Advisors's AUTL Position: Q2 2026 in Review

Citadel Advisors increased its Autolus Therapeutics (AUTL) stake by 51% in Q2 2026, buying an estimated $371K and bringing the position to 695,890 shares worth $1.11M. The position accounts for ﹤0.01% of the portfolio, ranked #7945.

Citadel Advisors first reported a position in AUTL in Q2 2019 and has held it in 27 quarters since. The position peaked at $18.3M in Q2 2021. 84 funds tracked by Wall St. Rank hold AUTL as of Q2 2026.

  • Citadel Advisors held 695,890 shares of Autolus Therapeutics worth $1.11M as of Q2 2026.
  • Citadel Advisors bought 236,486 Autolus Therapeutics shares in Q2 2026, an estimated $371K.
  • Autolus Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #7945 holding.
  • Citadel Advisors first reported a position in Autolus Therapeutics in Q2 2019 and has held it in 27 quarters since.
  • Citadel Advisors's Autolus Therapeutics position peaked at $18.3M in Q2 2021.
  • 84 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.